Law360, New York (November 04, 2008, 12:00 AM ET) -- Abbott Laboratories continues to fend off challenges to its blockbuster drug TriCor, accusing Biovail Corp. on Monday of infringing numerous patents when Biovail sought permission from federal regulators to market a generic version of the cholesterol treatment.
The complaint, lodged in the U.S. District Court for the Northern District of Illinois, claims Biovail’s abbreviated new drug application infringed three patents related to fenofibrate tablets that are exclusively licensed to Abbott by co-plaintiff Laboratories Fournier SA.
Biovail is looking to make and sell a generic version of...
Abbott Sues Biovail Over Generic TriCor
To view the full article, take a free trial now.
